Inclusion Criteria:  All patients must meet all the following criteria for study entry:  Age equal to or greater than 18 years of age. Diagnosis of HM (acute leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, lymphomas, myeloma, chronic myeloprolipherative disorders) at any stage/status. Third generation rapid molecular or antigen test positive for SARS-CoV-2 from February 2020 until May 2021 Treatment with anti SARS CoV 2 nMoAbs approved by AIFA Not hospitalized for COVID-19 at the time of nMoAbs administration Not on oxygen therapy at the time of nMoAbs administration  At least one of the following symptoms for no more than 10 days:  Fever Cough Anosmia Ageusia / dysgeusia Pharyngodynia Asthenia Headache Nausea Diarrhea Myalgia Dyspnea Tachypnea Signed written informed consent according to ICH/EU/GCP and national local laws (if applicable).  Exclusion Criteria:  1. Hematological diseases, other than HM.  2. Not tested positive for SARS-CoV-2  3. Patients in disease remission "off therapy" for more than 6 months  4. Immune plasma treatment in the previous two months